We love to hear from our listeners. Send us a message.

LyGenesis is  developing a pipeline of allogeneic cell therapies using the lymph node as an in vivo bioreactor to grow functioning ectopic organs. What sounds like science fiction to some is starting to look like a life changing therapy for millions of liver, kidney, pancreas, and thymus disease sufferers. The science behind it is being developed not in Boston, not in Philadelphia, nor in San Franciso, but right in the heart of the rust belt in Pittsburgh, PA. This week's episode of the Business of Biotech takes us there for a conversation with LyGenesis CEO Dr. Michael Hufford, Ph.D.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/